COMMON INITIAL DOSING REGIMENS

• A common dose is 50–100 mg intramuscularly every 1–2 weeks, with adjustments based on clinical goals and response. Higher doses (e.g., 200 mg weekly) may be used in cases of severe muscle wasting or specific therapeutic indications.

MECHANISM OF ACTION

• Nandrolone binds to androgen receptors in muscle, bone, and other tissues, promoting protein synthesis and inhibiting protein breakdown. It also increases red blood cell production by stimulating erythropoietin secretion. Unlike testosterone, nandrolone exhibits reduced conversion to estrogen, making it less likely to cause gynecomastia at therapeutic doses.

COMMON SIDE EFFECTS

• Endocrine: Suppression of natural testosterone production, potentially leading to hypogonadism if not properly managed.

• Metabolic: Alterations in lipid profiles, such as decreased HDL cholesterol and increased LDL cholesterol.

• Musculoskeletal: Joint pain relief and increased bone mineral density are benefits, but excessive doses may lead to tendon stiffness.

• General: Acne, hair thinning, and mild fluid retention are possible.

• Severe: Long-term use or high doses may increase the risk of cardiovascular events, liver dysfunction, or prostate enlargement.

CONTRAINDICATIONS

• Absolute: Known hypersensitivity to nandrolone or related compounds, active prostate or breast cancer, and significant cardiovascular or hepatic disease.

• Relative: Caution is advised in patients with a history of severe dyslipidemia, polycythemia, or untreated sleep apnea. Regular monitoring of hematocrit and lipid levels is recommended.

MORE INFORMATION

• FDA Safety Data Sheet not available